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Background: IgA nephropathy (IgAN) exhibits a variable course ranging from a benign condition to progressive
renal failure with a high proportion of patients undergoing end-stage renal disease in the long term. It is unclear
how to predict the risk of this progression. Mesangial C4d deposition has been found to be associated with a poor
prognosis. Our aim was to search histological lesions with possible prognostic value in IgAN biopsies performed at
the time of the diagnosis.
Methods: Clinical and laboratory records of 44 patients undergoing renal biopsy were reviewed. IgAN was
diagnosed in 32 patients and minimal change disease (MCD) in 12.
C4d deposition, glomerular endothelial cell area, glomerular and interstitial macrophages were evaluated in all
biopsies. Clinical and laboratory data were available in all IgAN patients at the time of diagnosis and in 21 patients
at the end of follow-up (mean follow-up 48.09 ± 19.69 months).
Results: All IgAN and MCD biopsies were C4d negative. The number of glomerular macrophages and the area of
glomerular endothelial cells in IgAN were greater than in MCD (P < 0.001 and P < 0.0001, respectively), indicating
glomerular inflammation associated with endothelial cell enlargement. Glomerular macrophages positively
correlated with diffuse IgA and fibrinogen immunoreactivity (P < 0.02 and P < 0.002, respectively).
Interstitial macrophages positively correlated with segmental glomerulosclerosis (P < 0.01) and tubular atrophy
(P < 0.001), according to the Oxford classification. They correlated with hypertension (P < 0.03) and renal
functional impairment both at the time of biopsy and at the end of follow-up. The receiver operating
characteristic analysis curve and a cut-off value of ≥19.5 macrophages per high power field showed 75.0%
sensitivity and 88.9% specificity in predicting worse clinical outcome. A Poisson generalized regression fit model
showed that hypertension and tubular atrophy were the most significant factors in predicting a high number of
interstitial macrophages.
Conclusions: The number of interstitial macrophages correlated with hypertension, histological damage,
functional impairment at the time of biopsy and worse outcome. A high number of interstitial macrophages in
C4d negative biopsies may allow the identification of patients at increased risk of progression to renal failure.
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IgA nephropathy (IgAN) has an incidence of approxi-
mately 2.5/100000/year in adults [1]. It is characterized
by the presence of glomerular IgA deposition in patients
with high levels of immune complexes formed by aber-
rantly glycosylated IgA and endogenous antiglycan anti-
bodies. IgA deposition is predominant, and IgG, IgM
and C3 deposition are frequently observed.
IgA-containing immune complexes deposited in the
glomeruli are associated with inflammation, proliferation
of mesangial cells, and synthesis of extracellular matrix
molecules [2]. The clinical course and the histopatho-
logical presentation of IgAN are highly variable [2–4].
IgAN may exist sub-clinically [3]. Although it usually
initiates as a benign condition, in 15–20 years 15–40%
of the patients progress to end-stage renal disease
(ESRD) [3–5]. Hypertension, some renal function pa-
rameters and histopathological features are known prog-
nostic risk factors. These parameters, however, may only
indicate the extent of the disease at a particular time,
such as the stage of the disease at the time of diagnosis
[3]. For instance, tubule-interstitial damage, associated
with a rapid development of ESRD [2–4], indicates an
advanced disease. The majority of patients present
haematuria with or without proteinuria, and a slowly
progressive course. A high percentage of these patients,
however, will experience a decline in renal function with
a rate of progression varying among patients [3, 4].
Thus, it would be important and also challenging to pre-
dict the risk of progression.
In renal transplant patients the C4d fragment of the
C4 complement component is released during activation
of the classic complement pathway; its deposition on the
surface of endothelial cells of peritubular and glomerular
capillaries is a marker of antibody-mediated acute rejec-
tion, and poor graft survival [6]. In IgA nephropathy
complement activation typically occurs via the alterna-
tive pathway, thus without C4d deposition [7]. However,
C4d deposition has been reported in approximately
25% of IgAN cases, [8] probably due to activation of
the mannose-binding lectin pathway [7]. As in patients
with antibody-mediated renal acute rejection, this is
predictive of a poor prognosis [8]. C4d deposition in
antibody-mediated acute rejection biopsies is associated
with a high number of interstitial macrophages and glo-
merulitis [9, 10]. Acute transplant glomerulitis, defined
by the presence of mononuclear cells-predominantly
macrophages-in the glomeruli and endothelial cell
enlargement [6] in some cases progresses to chronic
glomerulopathy, characterized by capillary basement
membrane multilayering, proteinuria and decline of
renal function [10, 11].
In IgAN the mechanism of haematuria is unknown,
endothelial cell damage and alterations of the glomerularbasal membrane may contribute to its development [4, 12].
Whether endothelial cell enlargement is present in IgAN
glomeruli has not been investigated. The aim of this study
was to evaluate the prognostic value of histological le-
sions such as glomerulitis and interstitial macrophages
in IgAN biopsies. The associations between histological
lesions and proteinuria, creatininemia, glomerular fil-
tration rate and hypertension were evaluated, and only
patients with C4d negative renal biopsies were included
in the study. The patients showed a classical clinical
presentation with haematuria and moderate protein-
uria. Minimal change disease (MCD) biopsies were
studied for comparison, considering that in this disease
glomerular changes at light microscopy and activation
of the complement system are not detected [13].
Methods
Patients
Clinical and laboratory records of 44 patients undergo-
ing renal biopsy consecutively between January 2003 and
December 2012 at our Institution were reviewed. IgAN
was diagnosed in 32 patients (21 males and 11 females,
mean age 35.9 ± 11.69 years) and MCD in 12 (6 males
and 6 females, mean age 39.50 ± 10.81 years). Patients
included in the study were more than 15 years of age
and underwent biopsy before any immune-suppressive
treatment. All IgAN patients showed C4d negative renal
biopsies. Patients with diabetes mellitus, autoimmune
diseases, abnormal hypergammaglobulinemia, and liver
diseases were excluded from the study. After biopsy, 7
patients were treated with renin-angiotensin system
blockers (RASB), 8 with corticosteroids, and 15 with
RASB and corticosteroids. Two patients with normal
renal function, proteinuria < 1 g/24 h and biopsies show-
ing only mild mesangial hypercellularity received no
treatment. Haematuria, proteinuria (g/24 h), serum
creatinine level, (reference range obtained by our clinical
laboratory: males = 0.66–1.25 mg/dl, females = 0.52–
1.04 mg/dl), blood pressure, and estimated glomerular
filtration rate (eGFR) (ml/min per 1.73 m2) were re-
corded at the time of biopsy. Hypertension was defined
as systolic blood pressure > 135 mmHg and/or diastolic
blood pressure > 85 mmHg or the use of anti-
hypertensive agents. In all hypertensive patients typical
vascular lesions were observed in the biopsies. Evalu-
ation of the clinical outcome was assessed using the
Kidney Disease Outcome Quality Initiative (KDOQI)
guidelines [14], which define 5 stages based on eGFR
evaluation (stage 1: eGFR ≥ 90 ml/min; 2: eGFR = 60–
89 ml/min; 3: eGFR = 30–59 ml/min; 4: eGFR = 15–30 ml/
min; 5: eGFR = <15 ml/min). Follow-up time was consid-
ered as the interval time between renal biopsy and the last
outpatient visit, haematuria, proteinuria, serum creatinine
levels and eGFR data were available for 21 patients (mean
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methylprednisolone (0.5–1 mg/kg/die) (n = 3), RASB
(n = 7) or methylprednisolone (1.5–1 mg/kg/die) in
combination with RASB (n = 9). Two patients received
no treatment. To evaluate the outcome the decline of
the eGFR was considered.
Histopathology and immunohistochemistry
Formalin-fixed paraffin-embedded sections were stained
with hematoxylin-eosin, PAS and Masson trichrome.
Direct immune-fluorescence was performed on fresh
frozen tissue with FITC-conjugated polyclonal anti-
bodies to detect IgG, IgM, IgA, C3 and fibrinogen
(Dako, Glostrup, Denmark). IgAN biopsies were scored
according to the Oxford [15] and the 3-Grade classifica-
tion [5]. According to the Oxford classification [15] each
glomerulus was scored for mesangial hypercellularity
(M0-M1, M1 indicated hypercellularity in more than
50% of glomeruli). The other parameters were endoca-
pillary hypercellularity (present/absent: E0-E1); segmen-
tal glomerulosclerosis (present/absent: S0-S1) and
tubular atrophy (T0 = < 25%, T1 = 26–50% and T2 = >
50% of the cortical area). According to the 3-Grade clas-
sification [5] biopsies were scored as G1 when a mild in-
crease in mesangial cells and no glomerulosclerosis or
tubulo-interstitial changes were detected, as G2 when at
least one of the following features was detected: moder-
ate increase in mesangial cellularity (focal or diffuse),
endocapillary proliferation, cellular crescent, (up to 50%
of glomeruli), focal segmental glomerulosclerosis, tubu-
lar atrophy and interstitial fibrosis (up to 1/3 of the cor-
tical area), as G3, when cellular crescents were present
in more than 50% of glomeruli, and/or fibrous crescents
or global glomerulosclerosis were present in more than
1/3 of glomeruli, and/or segmental glomerulosclerosis
involved more than 50% of glomeruli and/or tubular at-
rophy/interstitial fibrosis involved more than 1/3 of the
cortical area.
Sections were stained for immunohistochemistry using
the Bond Polymer Refine Detection method (Leica Bio-
system, Wetzlar, Germany) after high pH (pH 9.0) buff-
ered pre-treatment (Leica Biosystem), using the murine
monoclonal antibody (MoAb) anti-CD68 (Dako), recog-
nizing macrophages. Quantification of glomerular mac-
rophages was performed counting CD68+ cells in each
glomerulus and dividing the sum obtained in each bi-
opsy by the number of scored glomeruli (magnification
40). Interstitial macrophages in the cortical area were
counted in 10 high power fields (HPF) and the mean
number per HPF was reported (magnification × 40). For
detection of C4d paraffin sections were stained using the
XT Ultraview DAB v3 method (Ventana Medical Sys-
tem, Tucson, AZ, USA) after antigen retrieval by
pressure-cooking using a polyclonal anti-C4d antibody(Biomedica, Vienna, Austria). Biopsies from 12 patients
with MCD were used as negative controls, and two biop-
sies from patients with lupus glomerulonephritis as posi-
tive controls.
Staining of endothelial cells with anti-CD31 murine
MoAb (Dako) was performed using the Ultravision LP
polymer detection method (Thermo Fisher Scientific,
Freemont, CA, USA) after antigen retrieval by heating
the sections in Tris-EDTA buffer (pH 8.0). Primary anti-
bodies were replaced by irrelevant matched MoAb or
immune serum, as appropriate, as a control for non-
specific staining.
Morphometric analysis
Glomerular capillary loops were examined after CD31
immunostaining of endothelial cells as previously de-
scribed [16] using a Zeiss Axioskop 40 light microscope
(Carl Zeiss, Gottingen, Germany) equipped with a Cool-
snap Videocamera (Photometrics, Tucson, AZ, USA).
MetaMorph Software System (Universal Imaging Corp
Molecular Device Corp, CA, USA) was used to analyse
images. Only full cross-sectioned loops were measured.
Capillary loops showing endothelial cell nuclei were not
considered. Leukocytes or red cells within capillaries
were considered as part of the lumen. The external and
the internal capillary outlines were manually delineated
at × 40 magnification. The total area of the capillary
(TCA), and the area of the capillary lumen (LCA) were
automatically measured. The percentage of the total area
of the capillary occupied by endothelial cells (ECA%)
was defined as the ratio of (TCA - LCA)/TCA × 100).
Analyses were conducted on 44 biopsies (32 IgAN and
12 MCD), and 3 glomeruli were examined in each bi-
opsy. The area of capillary loops was measured in IgAN
glomeruli (1839 loops) and in MCD glomeruli (605
loops). Glomerular areas were evaluated as previously
described [17].
Statistical analyses
Results are expressed as mean ± SD. The Pearson χ2 test,
Wilcoxon/Kruskal-Wallis test, Pearson’s correlation test,
and one-way ANOVA were used for statistical analysis.
For all analyses statistical significance was defined as P < 0.05.
To estimate the performance as a prognostic marker
of interstitial macrophages per HPF the receiver oper-
ating characteristic (ROC) analysis curve was con-
structed and the area under the ROC curve (AUC)
and the corresponding 95% confidence interval (C.I. 95%)
were evaluated. The most appropriate cut-off value of
interstitial macrophages per HPF to predict clinical out-
come was determined by the point of interstitial macro-
phage number with maximum sum of sensitivity and
specificity. Poisson generalized regression fit model and
stepwise regression analysis were used to select the
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factorial regression model. Statistical analyses were
performed by JMP 11 software (SAS Institute Inc.
Cary, NC).
Results
Glomerular macrophages and immunofluorescence
pattern in IgAN and MCD biopsies
No significant differences in age and male/female ratio
were present between IgAN and MCD patients. In IgAN
biopsies the number of macrophages per glomerulus was
significantly higher than in MCD (6.31 ± 3.51 versus
1.11 ± 0.73, P < 0.0001). CD68+ macrophages in IgAN
and MCD glomeruli are shown in Fig. 1a and b. IgA,
IgM, IgG, C3 and fibrinogen immune-fluorescence stain-
ing was negative in all MCD biopsies. As required for
the diagnosis, all IgAN patients showed predominant
IgA immune-reactivity in the mesangial area of glom-
eruli, with diffuse positivity in 15 biopsies. Immune-
reactivities for IgG, IgM, C3 and fibrinogen were
observed in 11, 22, 32 and 18 biopsies, respectively. Dif-
fuse positivity was present in 3, 9, 11 and 6 biopsies, re-
spectively. The number of glomerular macrophages was
significantly higher in biopsies with diffuse IgA positivity
(n = 15) than in biopsies with IgA focal positivity (n = 17)
(7.82 ± 3.65 versus 4.97 ± 3.14, P < 0.02), and it was
markedly higher in biopsies with diffuse fibrinogen posi-
tivity (n = 6) than in biopsies with negative/focalFig. 1 Glomerular and interstitial macrophages in IgAN and MCD biopsies.
(original magnification × 20). b IgAN, numerous glomerular CD68+ cells (o
cells in the cortical area, (original magnification × 20). d IgAN, numerous infibrinogen positivity (n = 26) (10.18 ± 2.97 versus 5.41 ±
3.19, P < 0.002).
No significant difference was observed in the presence
of diffuse versus focal/negative IgG, IgM or focal C3
staining (data not shown).
This finding suggests a positive correlation between
the number of glomerular macrophages and the diffuse
distribution of IgA and fibrinogen.Glomerular endothelial cell area in IgAN and MCD
biopsies
The area of the capillary loop occupied by endothelial
cells (ECA%), was significantly higher in IgAN than in
MCD biopsies (76.81 ± 5.89 versus 61.83 ± 8.39, P < 0.0001)
(Fig. 2a). Glomerular areas in IgAN and MCD biopsies
were not significantly different (18698 ± 6553 and 16895 ±
6858 μ 2, respectively P = 0.427). Representative CD31+
glomerular endothelial cells in MCD and IgAN are shown
in Fig. 2b and c.C4d deposition in IgAN and MCD biopsies
Glomerular, mesangial or peritubular C4d staining was
not observed in either MCD or in IgAN biopsies
(Fig. 3b and c). In two biopsies of lupus glomerulo-
nephritis, included as positive controls, the glomerular
staining pattern was diffuse and segmental, and peri-
tubular capillaries were negative. Fig. 3a showsImmunohistochemical staining. a MCD, few glomerular CD68+ cells
riginal magnification × 20). c MCD, few scattered interstitial CD68+
terstitial CD68+ cells in the cortical area (original magnification × 20)
Fig. 2 Area occupied by endothelial cells in IgAN and MCD glomerular capillaries. The mean percentage of the total capillary loop area occupied
by endothelial cells (ECA%) was measured in 32 IgAN and in 12 MCD biopsies as described in Methods. a ECA% distribution in the two
groups of biopsies, in MCD the mean was significantly lower than in IgAN (61.83 ± 8.39 versus 76.81 ± 5.89, P < 0.0001), the standard
deviation for each value was < than 20 % and was omitted. b, c Glomeruli showing CD31 positive endothelial cells in IgAN and MCD (original
magnification × 20)
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ulonephritis (class IV).Glomerular and interstitial macrophages and histological
grading
The number of interstitial macrophages per HPF in the
cortical area was significantly higher in IgAN than in
MCD biopsies (18.29 ± 5.01 versus 11.25 ± 4.90, P < 0.0001).
CD68+ macrophages in IgAN and MCD interstitial cortical
area are shown in Fig. 1c and d.
According to the Oxford Classification [15], in IgAN
biopsies scored for mesangial cellularity (M0/M1) no dif-
ferences in the number of glomerular or interstitial
macrophages were observed (Table 1). Endocapillary
hypercellularity was scored as E0 in all biopsies. In biop-
sies scored for glomerulosclerosis as G1 and for tubular
atrophy as T1, the number of interstitial, but not that of
glomerular macrophages was significantly higher than in
G0 and T0 biopsies (P < 0.01 and P < 0.001, respectively)
(Table 1). Using the 3-Grade Classification [5], a low
number of macrophages was found to be associated with
the absence of glomerulosclerosis and tubule-interstitial
changes (G1) (P < 0.005) (Table 1).Glomerular and interstitial macrophages: clinical data and
outcome
In 32 IgAN patients haematuria, proteinuria, serum cre-
atinine levels, eGFR and blood pressure were examined
at the time of biopsy. At the end of follow-up haema-
turia, proteinuria, serum creatinine levels and eGFR data
were available for 21 patients (mean follow-up: 48.09 ±
19.69 months). At the time of biopsy microscopic
haematuria was present in 30 patients, gross haematuria
in one, and no haematuria in one (n = 32). At the end of
follow-up (n = 21), 14 patients showed microscopic
haematuria The mean level of proteinuria at the time of
biopsy was: 1.82 ± 1.19 g/24 h (n = 32). Proteinuria levels
at the time of biopsy and at the end of follow-up did not
correlate with glomerular or interstitial macrophages, or
with any of the other histological lesions studied. Inter-
estingly, in the 21 patients with available follow-up data
the mean level of proteinuria at the end of follow-up
(0.69 ± 0.78 g/24 h) was significantly lower than that ob-
served at the time of biopsy (1.61 ± 1.01 g/24 h, P < 0.002)
indicating a clear improvement of this parameter.
The number of interstitial, but not that of glomerular
macrophages was significantly higher in patients with in-
creased serum creatinine levels both at the time of
Fig. 3 C4d immune-reactivity in IgAN, MCD and lupus
glomerulonephritis biopsies. C4d staining was performed as described
in Materials and Methods. a C4d positivity in a lupus glomerulonephritis
biopsy (class IV) was observed on the surface of glomerular endothelial
cells (positive control) (original magnification × 20). b, c Absence
of endothelial or mesangial C4d staining in MCD (negative control)
and IgAN glomeruli. (original magnification × 20)
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respectively) (Table 2).
Moreover, a significant inverse correlation between
the number of interstitial but not of glomerular macro-
phages and the eGFR was observed at the time ofbiopsy (r = −0.463, P < 0.008 and r = −0.99, P = 0.5
respectively) and at end of the follow-up (r = −0.474,
P < 0.03 and r = −0.9, P = 0.3, respectively) (Fig. 4).
In patients without hypertension (n =15) the number
of interstitial macrophages per HFP was significantly
lower than in patients with hypertension (n = 17) (15.97
± 4.92 versus 20.93 ± 3.72, P < 0.03), whereas there was
no difference in the number of glomerular macrophages
(5.80 ± 3.62 versus 6.88 ± 3.68, P = 0.40). Patients with
hypertension were older than those without hyperten-
sion (42.26 ± 9.46 versus 29.70 ± 10.39 years, P < 0.001),
and in their biopsies one or more features of hyperten-
sive nephrosclerosis were present: arteriolar hyalinosis in
5 patients, arteriolar or arterial hyperplasia of smooth
muscle cells in 9, arterial proliferative intimal thickening
in 3, arterial intimal fibrosis in 3, and global glomerular
sclerosis in 1.
Evaluation of the clinical outcome was based on the
eGFR at time of biopsy and at the end of follow-up ac-
cording to the stages established by the KDOQI guide-
lines for chronic kidney disease [14]. The 21 patients
with follow-up data were considered. Twelve patients
(group 1) had a favourable outcome: 7 were in stage 1 at
the time of the biopsy and at the end of follow-up, and 5
showed an improved stage at the end of follow-up
(stages 2, 3, 3, 3 and 5 at the time of diagnosis; stages 1,
2, 1, 2 and 1 at the end of follow up, respectively). The
remaining 9 patients (group 2) had an unfavourable out-
come: 6 had no improvement (stages 2, 2, 3, 3, 3 and 3
at the time of the diagnosis and at the end of follow-up)
and 3 showed worse stages, with ESRD in two patients
(stages 1, 3 and 3 at the time of diagnosis; stages 2, 5
and 5, respectively, at the end of follow-up). In group 1
biopsies the number of interstitial macrophages per HPF
was significantly lower than in group 2 (17.34 ± 5.00 ver-
sus 22.15 ± 3.32, P < 0.02).
ROC curve analysis showed that the number of inter-
stitial macrophages predicted an unfavourable outcome.
AUC was 0.80 (C.I. 95% = 0.6–1.0; P < 0.0021) and a cut-
off value of ≥19.5 macrophages per HPF showed 75.0%
sensitivity and 88.9% specificity in predicting a worse
clinical outcome. Among 11 patients with ≥ 19.5 intersti-
tial macrophages per HPF, 8 (72.7%) had an unfavour-
able outcome, while among 10 patients with < 19.5
interstitial macrophages, only 1 (10%) had an unfavour-
able outcome (Fisher’s exact test: P < 0.0075). Therefore,
the number of interstitial macrophages per HPF resulted
a useful parameter to evaluate the clinical outcome.
The number of macrophages was not significantly as-
sociated with different therapeutic regimens in either the
favourable or unfavourable patient group (P = 0.48 and
P = 0.23, respectively). To control for covariance between
the factors associated with a high number of interstitial
macrophages a Poisson generalized regression fit model
Table 1 Number of interstitial macrophages correlated with Oxford and 3-Grade classification grading
Oxford Classification Glomerular macrophagesa P Interstitial macrophagesa P
M0 b (n = 22) 5.98 ± 3.70 0.4 18.25 ± 5.30 0.9
M1 (n = 10) 7.03 ± 3.56 18.40 ± 4.55
S0 c(n = 18) 6.13 ± 2.90 0.9 16.48 ± 4.37 < 0.01
S1 (n =14) 6.54 ± 4.51 20,65 ± 4.91
T0 d(n = 19) 6.18 ± 3.60 0.8 16.08 ± 4.57 < 0.001
T1 (n = 13) 6.13 ± 2.90 21.53 ± 3.79
3-Grade Classification Glomerular macrophagesa P Interstitial macrophagesa P
G1 e (n = 14) 5.95 ± 3.15 0.6 15.57 ± 4.30 < 0.005
G2 (n = 18) 6.59 ± 4,04 20.41 ± 4.55
aData expressed as means ± SD
bM =mesangial hypercellularity
cS = segmental glomerulosclerosis
dT = tubular atrophy
eG = grades of the 3-Grade classifications; none of the biopsies was scored as G3. M, S, T and G grades were scored as described in Materials and Methods
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was considered as a function of 6 variables: grade of the
3-Grade classification (G), segmental glomerulosclerosis
(S), tubular atrophy (T), hypertension, serum creatinine
level and eGFR. These variables were chosen since uni-
variate analyses showed that they were significantly cor-
related with interstitial macrophage number. The whole
model test yielded a significant fit (−Log Likelihood =
9.75; χ2 = 19.5; P < 0.0034) in predicting the number of
interstitial macrophages. We then performed variable se-
lection using stepwise regression analysis for the 6 vari-
ables used as explanatory effects in the Poisson
generalized regression. The criterion to add or delete a
variable in the model was based on F-statistics, with a
critical P-value of 0.05. Hypertension and tubular atro-
phy were selected as explanatory variables for the stand-
ard least square full factorial regression model. The
selected markers accurately validated the estimate of
interstitial macrophage number (actual versus predicted
number: r = 0.67, P < 0.0006). Interestingly, hyperten-
sion appeared significantly nested within tubular atro-
phy (P < 0.013) as its positive effect on interstitial
macrophage number occurred only in the absence of
tubular atrophy. As shown in Table 3 a significantlyTable 2 Macrophages and creatinine levels at the time of biopsy an
Serum creatinine level (mg/dl)a Glomerular macrophages
Males < 1.25, females < 1.04b 6.04 ± 3.657
Males > 1.25, females > 1.04c 6.65 ± 3.81
Males < 1.25, females < 1.04d 5.56 ± 2.81
Males > 1.25, females > 1.04e 6.29 ± 4.80
aData are expressed as means ± SD
bMean serum creatinine level at the time of biopsy in males < 1.25 and females < 1.
cMean serum creatinine level at the time of biopsy in males > 1.25 and females > 1.
dMean serum creatinine level at the end of the follow-up in males < 1.25 and femal
eMean serum creatinine level at the end of the follow-up in males > 1.25 and femalpositive effect of hypertension on the number of inter-
stitial macrophages occurred only when there was no
tubular atrophy. Tubular atrophy produced significantly
increased interstitial macrophages independent of the
hypertensive status.
Discussion
Identification of histological lesions with prognostic
value at the time of diagnosis is important to identify
IgAN patients with high risk of progression. We evalu-
ated C4d deposition, the area of glomerular endothelial
cells, glomerular and interstitial macrophages in IgAN
biopsies. We showed that a high number of interstitial
macrophages is associated with hypertension, unfavour-
able histological grading and deterioration the renal
function in C4d negative biopsy patients.
In agreement with the evidence of a good prognosis in
C4d negative patients [8] only two patients underwent
ESRD. Numerous glomerular macrophages and endothe-
lial cell enlargement characterized the glomerulitis.
Endothelial cell enlargement is one of the signs predict-
ing chronic glomerulopathy in antibody-mediated renal
transplant acute rejection [11]. The glomerular endothe-
lial cell area in IgAN has not yet been studied. We foundd at the end of follow-up
P Interstitial macrophages P
0.6 16.27 ± 4.83 < 0.007
20.89 ± 4.05
0.6 17.85 ± 4.88 < 0.03
22.62 ± 3.27
04 mg/dl (n =18) was 0.91 ± 0.16 mg/dl
04 mg/dl (n = 14) was 2.08 ± 1.89 mg/dl
es < 1.04 mg/dl (n = 14) was 0.90 ± 0.36 mg/dl
es > 1.04 mg/dl (n = 7) was 3.53 ± 2.77 mg/dl
Fig. 4 Interstitial macrophages and eGFR at the time of biopsy and end of follow-up. Glomerular CD68 positive cells and interstitial CD68 positive
cells in the cortical area per HPF were evaluated in IgAN biopsies as described in Materials and Methods. a No correlation was observed between
the number of glomerular macrophages and eGFR at the time of biopsy (r = −0.99, P = 0.5, n = 32). b A significant inverse correlation was present
between the number of interstitial macrophages and eGFR at the time of biopsy (r = −0.463, P < 0.008, n = 32). c No correlation was observed
between the number of glomeruli and eGFR at the end of follow-up (r = −0.9, P = 0.3, n = 21). d A significant inverse correlation was present at
the end of follow-up between the number of interstitial macrophages and eGFR (r = −0.474, P < 0.03, n = 21)
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to the area measured in acute transplant glomerulitis
[16]. Endothelial cell enlargement may indicate cell dam-
age and contribute to the development of haematuria,
with negative prognostic implications [4, 12].
The number of macrophages in glomeruli was posi-
tively correlated with diffuse deposition of IgA and fi-
brinogen, a result, to the best of our knowledge, shown
for the first time. This is in line with in vitro studies
investigating the mechanisms underlying the recruit-
ment of glomerular macrophages. Human mesangial
cells cultured with polymeric IgA from IgAN patients
produce RANTES and monocyte chemoattractant
protein-1 (MCP-1), potent chemotactic agents forTable 3 Number of interstitial macrophages according to
hypertension and tubular atrophy status
Tubular atrophy
Hypertension Absent Present
Absent 14.4 ± 0,971 23.4 ± 1,56
Present 20.9 ± 1,58 21.0 ± 1,27
Data are expressed as means ± SD. 1Kruskal-Wallis test: P < 0.0008macrophages [18]. Moreover, MCP-1 is produced by
human endothelial cells cultured with fibrinogen at
physiological concentrations [19].
Using two different histological classifications we
found that interstitial macrophages were associated with
glomerulosclerosis and tubular atrophy. In glomerular
diseases, glomerular damage precedes the interstitial fi-
brosis [20], thus, as also suggested by in vitro studies
[21], it is possible that macrophage-mediated mecha-
nisms may link these events.
Interstitial macrophages were previously correlated
with poor long-term prognosis, but not with impaired
renal function at the time of biopsy [22]. Other authors
have reported a correlation with impaired renal function
at the time of biopsy and long-term prognosis [23]. In
patients with C4d negative biopsies a high number of
interstitial macrophages correlated with impairment of
renal function at the time of biopsy and at the end of
follow-up, whereas the number of glomerular macro-
phages did not have any functional or prognostic value.
This is in line with the concept that macrophages in dif-
ferent localizations display different functions [24]. For
instance, in IgAN and in renal transplant rejection
Viola et al. Translational Medicine Communications  (2016) 1:7 Page 9 of 10biopsies the receptor for the chemokine RANTES
(CCRR5) was expressed by interstitial but not by glom-
erular macrophages [24].
A persistent high level of proteinuria is associated with
severe histological lesions, including high scores of
Oxford classification parameters [4, 23, 25, 26]. In our
study proteinuria levels did not correlate with histo-
logical findings. This might be due to the improvement
of proteinuria levels observed at the end of follow-up.
Hypertension is a well-established risk factor for IgAN
progression [3, 4]. For the first time in IgAN we found a
positive correlation between the number of interstitial
macrophages and hypertension. The systemic renin-
angiotensin-aldosterone system and the intrarenal renin-
angiotensin system contribute to the development of
hypertension [27]. In renal vascular hypertension the
presence of macrophages is attributed to the pro-
inflammatory activity of angiotensin II (ATII) [28]. In rat
models of ATII-induced hypertensive kidney injury mac-
rophages were found in the interstitium, associated with
MCP-1 expression in tubular cells and peritubular inter-
stitial cells [29]. Macrophages in turn promote hyperten-
sion [30, 31]. Infusion with ATII in mice was paralleled
by macrophage infiltration of the vessel walls, elastin
breakdown and collagen deposition [30] whereas M-
CSF-deficient mice lacking mature macrophages exhib-
ited a decreased hypertensive response [31]. We found
that the most relevant predictive factors for a high num-
ber of interstitial macrophages were hypertension and
tubular atrophy. The absence of hypertension showed a
protective effect, and in the absence of tubular atrophy
hypertension was predictive of an increased number of
interstitial macrophages. Notably, tubular atrophy was
predictive of a high number of interstitial macrophages
independently of the blood pressure status. RASB re-
duced blood pressure, MCP-1 expression and macro-
phage infiltration in some experimental hypertension
models [29]. However, when biopsies of patients with
hypertensive nephrosclerosis treated with RASB were
compared with those of untreated patients the number
of interstitial macrophages was not reduced [32]. Our
data suggest that the therapeutic regimens did not influ-
ence the prognostic value of the number of interstitial
macrophages. In IgAN the decision to treat patients with
RASB alone or to add corticosteroids depends on the
presence of signs associated with poor prognosis. In the
Kidney Disease Improving Global Outcome (KDIGO)
practice guidelines the administration of glucocorticoids
is suggested when proteinuria is higher than 1.5 g/day
and the eGFR is more than 50 ml/min after 6 months of
RASB therapy. The guidelines mention that histological
risk factors could be a good reason to combine RASB
with glucocorticoids, although no trials have been
performed [33]. Glucocorticoids reduce macrophageinfiltration and tubulo-interstitial injury in murine lupus
nephritis [34]. Thus, early combined treatment with
RASB and glucocorticoids may improve the long-term
prognosis in patients with pronounced macrophage
interstitial infiltration.
A limitation in our study is the small sample size, thus,
our results need to be validated with a larger cohort of
patients. In addition, it will be important to assess the
prognostic value of the number of interstitial macro-
phages in other primary glomerulonephritides.
Conclusions
A high number of interstitial macrophages in C4d nega-
tive biopsies of IgAN patients predicts an unfavourable
outcome. Our data encourage the identification of novel
anti-fibrotic therapies targeting macrophages.
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